Psyence Biomedical Ltd.(PBM)Earnings, Financials & Key Ratios
PBM•NASDAQ
$5.93
$39M mkt cap·Price updated May 6, 2026
AboutPsyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.Show more
- Revenue$0
- EBITDA-$3M-112.6%
- Net Income-$51M-738.3%
- EPS (Diluted)-7.85-1126.6%
- ROE-43.78%-1414.8%
- ROIC-1.69%-319.6%
- Interest Coverage-51.98
PBM Key Insights
Psyence Biomedical Ltd. (PBM) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 84 (top 16%)
- ✓Share count reduced 80.1% through buybacks
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
PBM Price & Volume
Psyence Biomedical Ltd. (PBM) stock price & volume — 10-year historical chart
Loading chart...
PBM Growth Metrics
Psyence Biomedical Ltd. (PBM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-418.16%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-827.11%
Return on Capital
10 Years-1%
5 Years-1%
3 Years-1%
Last Year-2.36%
PBM Peer Comparison
Psyence Biomedical Ltd. (PBM) competitors in Neuroscience and Psychiatry Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 CMPS | 937.8M | 9.76 | -3.17 | -335.93% | ||||
 MNMD | 2.04B | 20.69 | -10.04 | -55.3% | ||||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 | |
 CYBN | 303.86M | 6.09 | -13.66 | -81% | ||||
 LSCC | 17.15B | 125.19 | 5613.90 | 2.72% | 3.46% | 2.79% | 0.11 | |
 SILO | 1.89M | 0.42 | -0.35 | -70.41% | -101.36% | |||
 ENVB | 133.27K | 3.18 | -0.01 | -281.6% | ||||
 JAZZ | 14.34B | 228.57 | -39.14 | 4.88% | 0.66% | 0.71% | 1.26 |
Compare PBM vs Peers
Psyence Biomedical Ltd. (PBM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
PBM Income Statement
Psyence Biomedical Ltd. (PBM) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 240 | 0 |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -240▲ 0% | 0▲ 0% |
| Gross Margin % | - | - | - | - |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 334.29K | 1.29M | 2.75M | 2.47M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 1.72M | 1.63M | 1.8M | 2.4M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 137.24K | 1.61M | 954.59K | 75.14K |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | -1.52M | -1.94M | 0 | 0 |
| Operating Income | -334.29K▲ 0% | -1.29M▼ 287.1% | -2.75M▼ 112.7% | -2.47M▲ 0% |
| Operating Margin % | - | - | - | - |
| Operating Income Growth % | - | -287.08% | -112.66% | - |
| EBITDA | -334.29K | -1.29M | -2.75M | -2.47M |
| EBITDA Margin % | - | - | - | - |
| EBITDA Growth % | - | -287.08% | -112.65% | -91.09% |
| D&A (Non-Cash Add-back) | 0 | 0 | 240 | 120 |
| EBIT | 0 | 0 | -51.11M | -893.4K |
| Net Interest Income | 0 | 1.55K | -50.81K | 645.88K |
| Interest Income | 0 | 1.55K | 2.13K | 673.45K |
| Interest Expense | 0 | 0 | 52.94K | 27.57K |
| Other Income/Expense | 8.56M | 9.31M | -48.41M | -23.03M |
| Pretax Income | 8.23M▲ 0% | 8.01M▼ 2.6% | -51.16M▼ 738.3% | -25.5M▲ 0% |
| Pretax Margin % | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | 8.23M▲ 0% | 8.01M▼ 2.6% | -51.16M▼ 738.3% | -25.5M▲ 0% |
| Net Margin % | - | - | - | - |
| Net Income Growth % | - | -2.63% | -738.35% | -418.16% |
| Net Income (Continuing) | 8.23M | 8.01M | -51.16M | -25.5M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.25▲ 0% | -0.64▼ 356.0% | -7.85▼ 1126.6% | -1.90▲ 0% |
| EPS Growth % | - | -356% | -1126.56% | -827.11% |
| EPS (Basic) | 0.25 | -0.64 | -7.85 | - |
| Diluted Shares Outstanding | 32.67M | 32.67M | 6.52M | 13.39M |
| Basic Shares Outstanding | 32.67M | 32.67M | 6.52M | 13.39M |
| Dividend Payout Ratio | - | - | - | - |
PBM Balance Sheet
Psyence Biomedical Ltd. (PBM) balance sheet — assets, liabilities & shareholders' equity
| Line item | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 797.2K | 1.21M | 1.13M | 1.13K |
| Cash & Short-Term Investments | 431.9K | 15.96K | 762.8K | 733 |
| Cash Only | 648.28K | 128.68K | 762.8K | 733 |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 39.55K | 60.9K | 41.75K | 0 |
| Days Sales Outstanding | - | - | - | - |
| Inventory | -39.55K | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 0 | 917.12K | 0 | 71 |
| Total Non-Current Assets | 255.25M | 257.73M | 5.49K | 5 |
| Property, Plant & Equipment | 0 | 0 | 5.49K | 5 |
| Fixed Asset Turnover | - | - | - | 0.00x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 255M | 257.73M | 0 | 45.18M |
| Other Non-Current Assets | 248.65K | 0 | 0 | 0 |
| Total Assets | 256.22M▲ 0% | 258.93M▲ 1.1% | 1.13M▼ 99.6% | 1.13K▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 1.06% | -99.56% | -382.11% |
| Total Current Liabilities | 68.7K | 14.27M | 12.1M | 12.1K |
| Accounts Payable | 36.89K | 1.63M | 562.35K | 562 |
| Days Payables Outstanding | - | - | 855.24K | - |
| Short-Term Debt | 0 | 685K | 10.45M | 10.45K |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | -63.06K | 11.8M | 968.51K | 969 |
| Current Ratio | 11.60x | 0.08x | 0.09x | 0.09x |
| Quick Ratio | 12.18x | 0.08x | 0.09x | 0.09x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 16.24M | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 16.24M | 0 | 0 | 0 |
| Total Liabilities | 19.58M | 14.27M | 12.1M | 12.1K |
| Total Debt | 0 | 685K | 10.45M | 10.45K |
| Net Debt | -648.28K | -128.68K | 9.71M | 9.71K |
| Debt / Equity | - | 0.00x | - | -0.95x |
| Debt / EBITDA | - | - | - | -0.00x |
| Net Debt / EBITDA | - | - | - | -0.00x |
| Interest Coverage | - | - | -51.98x | -32.41x |
| Total Equity | 236.65M▲ 0% | 244.66M▲ 3.4% | -10.97M▼ 104.5% | -10.97K▲ 0% |
| Equity Growth % | - | 3.39% | -104.48% | -400.21% |
| Book Value per Share | 7.24 | 7.49 | -1.68 | -0.00 |
| Total Shareholders' Equity | 236.65M | 244.66M | -10.97M | -10.97K |
| Common Stock | 255M | 258.55M | 46.13M | 46.13K |
| Retained Earnings | -18.36M | -13.9M | -57.46M | -57.46K |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 361.06K | 361 |
| Minority Interest | 0 | 0 | 0 | 0 |
PBM Cash Flow Statement
Psyence Biomedical Ltd. (PBM) cash flow — operating, investing & free cash flow history
| Line item | Mar'22 | Mar'23 | Mar'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -1.4M | -519.6K | -2.95M | -2.95M |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | 62.79% | -466.85% | -329.65% |
| Net Income | -1.86M | -24.49K | -51.16M | -25.5M |
| Depreciation & Amortization | 0 | 0 | 240 | 0 |
| Stock-Based Compensation | 332.07K | 221.29K | 317.88K | 159 |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | -661.96K | 49.07M | -1.85M |
| Working Capital Changes | 129.74K | -54.44K | -1.17M | 787.37K |
| Change in Receivables | 100.05K | 0 | 107.62K | 767.9K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 0 | 0 | 0 | 0 |
| Cash from Investing | -32.04K | 0 | -5.73K | 246.83M |
| Capital Expenditures | 0 | 0 | -5.73K | -4 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 254.97M | 0 | 0 | 0 |
| Cash from Financing | -1.63M | 1.17M | 2.35M | -245.81M |
| Debt Issued (Net) | 0 | 0 | 2.35M | 0 |
| Equity Issued (Net) | 0 | 0 | 0 | -2M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | -247.42M |
| Other Financing | -1.63M | 1.17M | 0 | 1.61M |
| Net Change in Cash | -3.06M▲ 0% | -519.61K▲ 83.0% | -601.09K▼ 15.7% | -40.43K▲ 0% |
| Free Cash Flow | -839.17K▲ 0% | -519.6K▲ 38.1% | -2.95M▼ 468.0% | -1.05M▲ 0% |
| FCF Margin % | - | - | - | - |
| FCF Growth % | - | 38.08% | -467.95% | -102.8% |
| FCF per Share | -0.03 | -0.02 | -0.45 | -0.45 |
| FCF Conversion (FCF/Net Income) | -0.17x | -0.06x | 0.06x | 0.04x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
PBM Key Ratios
Psyence Biomedical Ltd. (PBM) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | 3.33% | -43.78% | 19522.88% |
| Return on Invested Capital (ROIC) | -0.4% | -1.69% | -1.69% |
| Debt / Equity | 0.00x | - | -0.95x |
| Interest Coverage | - | -51.98x | -32.41x |
| FCF Conversion | -0.06x | 0.06x | 0.04x |
PBM Frequently Asked Questions
Psyence Biomedical Ltd. (PBM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Psyence Biomedical Ltd. (PBM) grew revenue by 0.0% over the past year. Growth has been modest.
Psyence Biomedical Ltd. (PBM) reported a net loss of $25.5M for fiscal year 2023.
Dividend & Returns
Psyence Biomedical Ltd. (PBM) has a return on equity (ROE) of -43.8%. Negative ROE indicates the company is unprofitable.
Psyence Biomedical Ltd. (PBM) had negative free cash flow of $1.1M in fiscal year 2023, likely due to heavy capital investments.
Explore More PBM
Psyence Biomedical Ltd. (PBM) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates